教員紹介

山田克宣

山田克宣: 教授

所属	経済学部経済学科経済学研究科
学位	博士（経済学）
専門	行動経済学
ジャンル	経済/経済理論
コメント	経済学理論を背景にもつ対人実験と、そのデータ分析を行っています。特に離散選択実験の枠組みで行う支払意思額の推計と、ランダム介入実験による因果推論を中心に扱っています。
リサーチマップ	https://researchmap.jp/kyamada

学歴/経歴

学歴

2001年4月 - 2006年3月
京都大学大学院経済学研究科
1996年4月 - 2000年3月
京都大学経済学部

経歴

2021年4月 - 現在
近畿大学経済学部教授
2014年4月 - 2021年3月
近畿大学経済学部准教授
2011年4月 - 2014年3月
大阪大学社会経済研究所 The Institute of Social and Economic Research 講師
2013年8月 - 2013年11月
Academia Sinica Visiting researcher
2012年11月 - 2013年7月
Universitat Autonoma de Barcelona Visiting researcher
2008年10月 - 2011年3月
大阪大学社会経済研究所 The Institute of Social and Economic Research 特任研究員（常勤）
2010年10月 - 2010年10月
Paris School of Economics Visiting researcher
2006年4月 - 2008年9月
大阪大学大学院経済学研究科 Graduate School of Economics 日本学術振興会特別研究員(PD)
2000年4月 - 2000年12月
東京三菱銀行

研究活動情報

研究分野

人文・社会, 経済政策
ライフサイエンス, 神経科学一般

研究キーワード

行動経済学, Neuro economics, 脳プロ, マクロ経済学

論文

The Constructive and Destructive Power of Social Norms in the Presence of Authoritative Influence
Shuhei Kitamura; Katsunori Yamada
American Psychologist 80 (3) 345-358 2025年8月 [査読有り]
A periodic split attractor reconstruction method facilitates cardiovascular signal diagnoses and obstructive sleep apnea syndrome monitoring
Ze Zhang; Kayo Hirose; Katsunori Yamada; Daisuke Sato; Kanji Uchida; Shinjiro Umezu
Heliyon 10 (15) e35623-e35623 2024年8月 [査読有り]
The Joneses in Japan: Income Comparisons and Financial Satisfaction
Clark A; C. Senik; K. Yamada
Japanese Economic Review 73 351-372 2022年 [査読有り]

Feeling Rich or Looking Rich? Quantifying Self-Image and Social-Image Motives , Nicolas Bottan; Ricardo Perez-Truglia; Hitoshi Shigeoka; Katsunori Yamada , NBER working paper , 34094 , 2025年8月
Nightless City: Impacts of Politicians' Questions on Overtime Work of Bureaucrats , Natsuki Arai; Masashige Hamano; Munechika Katayama; Yuki Murakami; Katsunori Yamada , SSRN , 2025年
Unveiling Willingness to Pay for iPSC-Based Retinal Cell therapy through Discrete Choice Experiments , Katsunori Yamada; Daiki Sakai; Masakazu Hiraoka; Saki Hiyoshi; Tomoki Otani; Michiko Mandai; Tadao Maeda; Kana Hatakenaka; Masayo Takahashi , PsyArXiv , 2024年9月14日
概要：<p>Advanced technologies risk becoming obsolete if not successfully integrated into society. One contributing factor for the societal setback is the absence of procedures for setting appropriate prices for deliverable products, which are essential for creating mutually beneficial scenarios for both supply and demand. Among those product, the therapeutic ap- plication of induced pluripotent stem cell (iPSC) technology, particularly in ophthalmology, holds significant promise for addressing unmet healthcare needs. However, its progress is currently stalled at the social implementation stage due to difficulties in setting an appropri- ate price. Traditional pricing methods, such as cost-based calculations, often underestimate the true value of new medical treatments because of the lack of existing benchmarks for comparison or projected future medical demands for rare diseases. Additionally, cost-benefit methods that reflect Quality-Adjusted Life Year (QALY) are sometimes used for pricing new technologies. However, for the treatment of eye diseases, it is considered more appropriate to set prices that also account for the psychological burden associated with blindness. Using tools from behavioral economics in hypothetical discrete choice experiments, we estimated the willingness to pay (WTP) – reflecting psychological monetary values – for new eye disease treatments among healthy subjects (n = 1,200) and actual patients (n = 50). The estimated WTPs for a scenario that most accurately describes the current therapeutic technology that improves a patient’s vision are more than 15 times the unconditional average annual income in Japan (before tax) among healthy subjects. The point estimates of WTPs from actual patients are even higher, as expected, given their risk of incurable visual impairment. These results indicate a strong demand for the social implementation of iPSC-based retinal cell therapy. Incorporating social demand into drug pricing, as part of patient and public in- volvement in medicine, could encourage healthcare providers to explore innovative therapies and support their sustainable implementation.</p>